LT3324932T - Kompozicijos ir būdai, skirti liofilinėms nanodalelių formoms - Google Patents

Kompozicijos ir būdai, skirti liofilinėms nanodalelių formoms

Info

Publication number
LT3324932T
LT3324932T LTEP16828602.9T LT16828602T LT3324932T LT 3324932 T LT3324932 T LT 3324932T LT 16828602 T LT16828602 T LT 16828602T LT 3324932 T LT3324932 T LT 3324932T
Authority
LT
Lithuania
Prior art keywords
nanoparticle
compositions
methods
lyophile forms
lyophile
Prior art date
Application number
LTEP16828602.9T
Other languages
English (en)
Inventor
Wenbin Ying
Roger Adami
Yuwei Wang
Haiqing Yin
Liping Wang
Dong Liu
Original Assignee
Nitto Denko Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nitto Denko Corporation filed Critical Nitto Denko Corporation
Publication of LT3324932T publication Critical patent/LT3324932T/lt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51Nanocapsules; Nanoparticles
    • A61K9/5107Excipients; Inactive ingredients
    • A61K9/513Organic macromolecular compounds; Dendrimers
    • A61K9/5161Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/713Double-stranded nucleic acids or oligonucleotides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40Cyclodextrins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Liposomes
    • A61K9/1271Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51Nanocapsules; Nanoparticles
    • A61K9/5107Excipients; Inactive ingredients
    • A61K9/5123Organic compounds, e.g. fats, sugars
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111General methods applicable to biologically active non-coding nucleic acids
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/14Type of nucleic acid interfering N.A.
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00Applications; Uses
    • C12N2320/30Special therapeutic applications
    • C12N2320/32Special delivery means, e.g. tissue-specific
LTEP16828602.9T 2015-07-22 2016-07-22 Kompozicijos ir būdai, skirti liofilinėms nanodalelių formoms LT3324932T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562195356P 2015-07-22 2015-07-22
PCT/US2016/043537 WO2017015552A1 (en) 2015-07-22 2016-07-22 Compositions and methods for nanoparticle lyophile forms

Publications (1)

Publication Number Publication Date
LT3324932T true LT3324932T (lt) 2021-04-26

Family

ID=57834582

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEP16828602.9T LT3324932T (lt) 2015-07-22 2016-07-22 Kompozicijos ir būdai, skirti liofilinėms nanodalelių formoms

Country Status (23)

Country Link
US (3) US10300018B2 (lt)
EP (1) EP3324932B1 (lt)
JP (2) JP6875373B2 (lt)
KR (1) KR20180030698A (lt)
CN (2) CN108024957B (lt)
AU (1) AU2016297153B2 (lt)
BR (1) BR112018001178A2 (lt)
CA (1) CA2992849C (lt)
CY (1) CY1123984T1 (lt)
DK (1) DK3324932T3 (lt)
EA (1) EA035761B1 (lt)
ES (1) ES2862191T3 (lt)
HR (1) HRP20210523T1 (lt)
HU (1) HUE053990T2 (lt)
IL (2) IL288342B2 (lt)
LT (1) LT3324932T (lt)
MX (1) MX2018000891A (lt)
PL (1) PL3324932T3 (lt)
PT (1) PT3324932T (lt)
RS (1) RS61607B1 (lt)
SI (1) SI3324932T1 (lt)
TW (1) TWI732773B (lt)
WO (1) WO2017015552A1 (lt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3085694A1 (en) 2017-12-12 2019-06-20 Lead Biotherapeutics Ltd. Solid lipid nanoparticle for intracellular release of active substances and method for production the same
CN108813619A (zh) * 2018-07-19 2018-11-16 广州市汉廷食品有限公司 一种无公害食品添加剂及其制备工艺
BR112021004929A2 (pt) 2018-09-28 2021-06-01 Nutcracker Therapeutics, Inc. peptídeos catiônicos terciários amino-lipidados para entrega de ácido nucleico
JP2022512077A (ja) * 2018-11-16 2022-02-02 日東電工株式会社 Rna干渉送達製剤及び悪性腫瘍のための方法
WO2021060440A1 (ja) * 2019-09-26 2021-04-01 日油株式会社 脂質ナノ粒子の凍結乾燥組成物
WO2022036170A1 (en) * 2020-08-14 2022-02-17 Arcturus Therapeutics, Inc. Method of lyophilizing lipid nanoparticles
WO2023064891A1 (en) 2021-10-14 2023-04-20 Hemoshear Therapeutics, Inc. Compositions and methods of treating diseases associated with bile acid transporter
CN116643056A (zh) * 2022-02-15 2023-08-25 厦门万泰凯瑞生物技术有限公司 促甲状腺激素受体复合物、试剂盒、制备方法和用途

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4537683A (en) 1982-02-01 1985-08-27 Rohm And Haas Company Trihalomethane precursor removal using ion exchange emulsions
US4537883A (en) * 1982-11-12 1985-08-27 Mead Johnson & Company Lyophilized cyclophosphamide
US4927571A (en) 1987-05-18 1990-05-22 Liposome Technology, Inc. Preparation of injectable doxorubicin/liposome suspension
US20040121983A1 (en) * 2002-08-12 2004-06-24 Council Of Scientific And Industrial Research Method for treating leishmaniasis using methyl-beta-cyclodextrin
CA2497792C (en) * 2002-09-06 2014-08-05 Insert Therapeutics, Inc. Cyclodextrin-based polymers for therapeutics delivery
WO2005000271A1 (en) 2003-06-04 2005-01-06 Georgetown University Method for improving stability and shelf-life of liposome complexes
US20060110441A1 (en) 2004-10-28 2006-05-25 Harry Wong Lyophilized liposome formulations and method
CA2587337A1 (en) * 2004-11-19 2006-05-26 Novosom Ag Improvements in or relating to pharmaceutical compositions for local administration
EP2123288B1 (en) * 2007-02-09 2011-05-04 National University Corporation Nara Institute of Science and Technology C70 fullerene-containing liposome, method for producing the same, and use of the same
US8357401B2 (en) * 2009-12-11 2013-01-22 Bind Biosciences, Inc. Stable formulations for lyophilizing therapeutic particles
WO2011103150A2 (en) 2010-02-18 2011-08-25 Cephalon, Inc. Lyophilized preparations of bendamustine
US20110237686A1 (en) 2010-03-26 2011-09-29 Cerulean Pharma Inc Formulations and methods of use
CN102018672B (zh) * 2010-11-29 2013-09-18 广州朗圣药业有限公司 一种水溶性药物的脂质体冻干组合物及其制备方法
US9011903B2 (en) 2011-06-08 2015-04-21 Nitto Denko Corporation Cationic lipids for therapeutic agent delivery formulations
EP3998064A1 (en) * 2011-06-08 2022-05-18 Translate Bio, Inc. Cleavable lipids
JP6133308B2 (ja) 2011-10-21 2017-05-24 セレーター ファーマシューティカルズ インコーポレイテッド 凍結乾燥リポソーム
US9579338B2 (en) * 2011-11-04 2017-02-28 Nitto Denko Corporation Method of producing lipid nanoparticles for drug delivery
SI2773326T1 (sl) * 2011-11-04 2019-04-30 Nitto Denko Corporation Metoda za sterilno proizvodnjo delcev lipidno-nukleinske kisline
WO2013149013A1 (en) 2012-03-28 2013-10-03 Discovery Laboratories, Inc. Lyophilization of synthetic liposomal pulmonary surfactant
US9877919B2 (en) * 2012-03-29 2018-01-30 Translate Bio, Inc. Lipid-derived neutral nanoparticles
AU2013270685B2 (en) 2012-06-08 2017-11-30 Nitto Denko Corporation Lipids for therapeutic agent delivery formulations
US20140271815A1 (en) 2013-03-15 2014-09-18 Aryo Sorayya Heat-and freeze-stable vaccines and methods of making and using same

Also Published As

Publication number Publication date
WO2017015552A1 (en) 2017-01-26
HRP20210523T1 (hr) 2021-05-14
CN108024957B (zh) 2021-08-24
CA2992849A1 (en) 2017-01-26
KR20180030698A (ko) 2018-03-23
EP3324932A1 (en) 2018-05-30
IL257029A (en) 2018-03-29
CA2992849C (en) 2023-06-13
MX2018000891A (es) 2018-06-11
JP2021119161A (ja) 2021-08-12
ES2862191T3 (es) 2021-10-07
SI3324932T1 (sl) 2021-07-30
AU2016297153A1 (en) 2018-03-01
AU2016297153B2 (en) 2021-02-25
EP3324932B1 (en) 2021-03-10
CN113679689B (zh) 2023-09-01
TW201717914A (zh) 2017-06-01
EA035761B1 (ru) 2020-08-06
TWI732773B (zh) 2021-07-11
DK3324932T3 (da) 2021-04-06
IL288342A (en) 2022-01-01
CN113679689A (zh) 2021-11-23
US20190231695A1 (en) 2019-08-01
US10300018B2 (en) 2019-05-28
CN108024957A (zh) 2018-05-11
BR112018001178A2 (pt) 2018-09-11
IL257029B (en) 2021-12-01
IL288342B1 (en) 2023-10-01
EP3324932A4 (en) 2019-03-06
CY1123984T1 (el) 2022-05-27
PL3324932T3 (pl) 2021-07-05
US11737982B2 (en) 2023-08-29
HUE053990T2 (hu) 2021-08-30
RS61607B1 (sr) 2021-04-29
JP7268079B2 (ja) 2023-05-02
US20240000710A1 (en) 2024-01-04
JP6875373B2 (ja) 2021-05-26
EA201890367A1 (ru) 2018-06-29
PT3324932T (pt) 2021-04-06
JP2018521083A (ja) 2018-08-02
US20170020819A1 (en) 2017-01-26
IL288342B2 (en) 2024-02-01

Similar Documents

Publication Publication Date Title
HK1257295A1 (zh) 用於免疫腫瘤學的組合物和方法
IL286025A (en) Nanoparticle preparations and immunotherapy methods
GB2546350B (en) Compositions and methods
GB2535253B (en) Compositions and methods
IL288342A (en) Formulations and methods for lyophilic nanoparticulate forms
GB201718876D0 (en) Antithrombin-heparin compositions and methods
IL258292A (en) Methods and compositions for reducing metastases
IL246879A0 (en) Preparations of Epilimod and methods of using them
HK1245158A1 (zh) 阿吡莫德組合物及其使用方法
ZA201605109B (en) Compositions and methods for treating neutropenia
HK1223837A1 (zh) 減少過劑量的組合物和方法
GB201705626D0 (en) Compositions and methods
ZA201807665B (en) Methods and compositions
GB201715820D0 (en) Compositions and methods
GB201512996D0 (en) Compositions and methods
IL253174A0 (en) Nanoparticles and methods for their preparation
PT3160263T (pt) Composições para prevenção de infeções
GB201514413D0 (en) Compositions and methods
GB201402915D0 (en) Compositions and methods
ZA201807782B (en) Methods and compositions
IL256261B (en) Hide1 compositions and methods
GB201521306D0 (en) Compositions comprising nanoparticles and methods thereof
GB201522554D0 (en) Methods and compositions
GB201521083D0 (en) Compositions for treatment and methods thereof
GB201518167D0 (en) Methods and compositions